Business Description
Forma Therapeutics Holdings Inc
NAICS : 541714
SIC : 2834
300 North Beacon Street, Suite 501, Watertown, MA, USA, 02472
Description
Forma Therapeutics Holdings Inc is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of novel therapeutics to transform the lives of patients with rare hematologic diseases and cancers. The firm's pipeline products are Etavopivat, FT-7051, FT-8225, and others.
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 12.16 | |||||
Equity-to-Asset | 0.87 | |||||
Debt-to-Equity | 0.08 | |||||
Debt-to-EBITDA | -0.17 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 1/9 | |||||
Altman Z-Score | 0 | |||||
Beneish M-Score | 0 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -100 | |||||
3-Year EPS without NRI Growth Rate | -375.3 | |||||
3-Year FCF Growth Rate | 35.3 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 83.75 | |||||
9-Day RSI | 79.52 | |||||
14-Day RSI | 75.53 | |||||
6-1 Month Momentum % | -26.23 | |||||
12-1 Month Momentum % | -64.51 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 12.74 | |||||
Quick Ratio | 12.74 | |||||
Cash Ratio | 11.83 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -61 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -38.09 | |||||
ROA % | -34.37 | |||||
ROIC % | -254.8 | |||||
ROC (Joel Greenblatt) % | -647.65 | |||||
ROCE % | -36.65 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 1.37 | |||||
Price-to-Tangible-Book | 1.37 | |||||
EV-to-EBIT | -1.07 | |||||
EV-to-Forward-EBIT | -0.94 | |||||
EV-to-EBITDA | -1.08 | |||||
EV-to-Forward-EBITDA | -0.95 | |||||
EV-to-FCF | -1.16 | |||||
Price-to-Net-Current-Asset-Value | 1.55 | |||||
Price-to-Net-Cash | 1.69 | |||||
Earnings Yield (Greenblatt) % | -93.46 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:FMTX
Executives
EMBED
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 0 | ||
EPS (TTM) ($) | -4 | ||
Beta | 0 | ||
Volatility % | 54.71 | ||
14-Day RSI | 75.53 | ||
14-Day ATR ($) | 0.718851 | ||
20-Day SMA ($) | 9.3145 | ||
12-1 Month Momentum % | -64.51 | ||
52-Week Range ($) | 4.95 - 25.21 | ||
Shares Outstanding (Mil) | 47.85 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 1 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Forma Therapeutics Holdings Inc Filings
Document | Form | Filing Date | ||
---|---|---|---|---|
No Filing Data |